Untangling targeted protein degrader (TPD) clinical development
Navigate the complexities of TPD target engagement and resistance mechanisms with expert biomarker services
Targeted protein degraders (TPDs) offer great promise in treating some of the most challenging diseases. But clinical development is fraught with complex biomarker challenges.
To succeed, you must deeply understand your TPD’s mechanisms of action, accurately monitor target degradation to optimize dosing, and unveil the causes of resistance — which is no easy feat.
Download our brochure today and find out how, with deep TPD expertise and a comprehensive multi-omics approach, we can steer you through the complexities of understanding TPD potency, dose optimization, and resistance mechanisms, helping you increase your chances of TPD clinical development success.
Download the brochure
As a global research organization, we prioritize your study goals and clinical trial needs above all else. We aim to provide you with easy, accessible, and comprehensive technologies spanning a multitude of therapeutic areas. Discover our range of services in immunology, histopathology, proteomics, genomics, as well as related ML/AI and sample logistics services.